Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report

Combined radioimmunotherapy is currently being investigated to treat patients with cancer. Anti-programmed cell death-1 (PD-1) immunotherapy offers the prospect of long-term disease control in solid tumors. Radiotherapy has the ability to promote immunogenic cell death leading to the release of tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Merhi, Maysaloun, Raza, Afsheen, Inchakalody, Varghese Philipose, Siveen, Kodappully S, Kumar, Deepak, Sahir, Fairooz, Mestiri, Sarra, Hydrose, Shereena, Allahverdi, Niloofar, Jalis, Munir, Relecom, Allan, Al Zaidan, Lobna, Hamid, Mohamed Sir Elkhatim, Mostafa, Mai, Gul, Abdul Rehman Zar, Uddin, Shahab, Al Homsi, Mohammed, Dermime, Said
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484873/
https://www.ncbi.nlm.nih.gov/pubmed/32913031
http://dx.doi.org/10.1136/jitc-2020-001278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484873/
https://www.ncbi.nlm.nih.gov/pubmed/32913031
http://dx.doi.org/10.1136/jitc-2020-001278

Ejemplares similares